All News

Based on findings of a study conducted by the Michael J. Fox Foundation for Parkinson Research, the individual annual economic burden for a patient with Parkinson disease amounted to $52,000 in 2017, with nonacute institutional care, inpatient hospitalization, and outpatient care indicated as the largest drivers of cost among differing coverage plans.

Bristol Myers Squibb announced the commercial launch of Zeposia (ozanimod) for relapsing multiple sclerosis (RMS). The oral treatment is the first and only approved sphingosine-1-phosphate receptor modulator with no genetic test or first dose observation at initiation.

Research has established an association between social risk factors and child health outcomes, while professional medical organizations have endorsed screening for such factors in clinical settings. Providing an in-person patient navigator to address family social needs leads to a decrease in child health care utilization, according to a study published in JAMA Network Open.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo